Evidence · Systematic review or meta-analysis
Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data.
- Mechanical ventilation
- Medical
- Neurodevelopmental follow-up
- Respiratory
This paper is from 2017, more than five years ago. Newer evidence may have been published since.
Summary
Updated individual patient data meta-analysis of six randomised controlled trials comparing vaginal progesterone with placebo or no treatment in asymptomatic women with twin pregnancies and a mid-trimester sonographic short cervix. It included 303 women and their 606 fetuses or infants. Vaginal progesterone was associated with reduced preterm birth at under 30 to under 35 weeks, lower neonatal mortality and improvements in some measures of neonatal morbidity. No harmful effects on childhood neurodevelopment were demonstrated. The work is primarily obstetric but relevant to perinatal counselling and neonatal outcomes.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.